JSPRW
Jasper Therapeutics IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-3.84
Beta
3.07
52W High
$0.15
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Jasper Therapeutics Inc
Jasper Therapeutics Inc. is a clinical-stage biotechnology firm focused on transforming the treatment landscape for severe diseases through its proprietary hematopoietic cell transplantation platform. The company's lead therapeutic candidate, JSP191, has shown encouraging results in early clinical trials for blood disorders, indicating its potential to improve patient outcomes. Backed by a strong pipeline and a seasoned leadership team, Jasper Therapeutics is poised to make significant strides in cell therapy and regenerative medicine, advancing its innovative treatments through critical stages of clinical development.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-69.94M |
| Operating Margin | 0.00% |
| Return on Equity | -244.20% |
| Return on Assets | -112.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.12 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $21.97M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
96.14%
HV 20-Day
77.05%
HV 30-Day
83.39%
HV 60-Day
128.96%
HV Rank
—
Volatility is currently expanding
Data last updated: 7/9/2026